Novo Nordisk, Metaphore
Novo Nordisk struck a $600 million deal to find the next weight loss wonder drug
The company behind blockbuster drugs Ozempic and Wegovy wants to keep the gravy train running. Expanding an earlier deal, it announced Thursday that it will pay U.S. company Metaphore Biotechnologies as much as $600 million to help it develop new medicines.
1 in 8 adults have taken popular drugs used for weight loss, poll says
(CNN) - About one in eight adults said they have taken a GLP-1 drug like Ozempic or Mounjaro, according to a new poll from KFF. About 6% of respondents say they are currently taking the popular drugs.
Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster
The company will collaborate with a biotech founded by Flagship Pioneering, the venture capital firm that created Moderna.
‘Ozempic Breasts’ Side Effect Reported by People Taking Weight Loss Drugs
People taking GLP-1 weight loss drugs like Ozempic and Wegovy are reporting unexpected changes in the size and shape of their breasts.
Wegovy now in Canada: Who should (and shouldn’t) use the weight-loss drug
After years of persistent shortages, Canadians can now access Wegovy, an on-label weight loss medication, made by the same manufacturers of Ozempic.
Novo Nordisk Partners With Metaphore Biotechnologies on New Obesity Drugs
By Helena Smolak Ozempic maker Novo Nordisk signed a research collaboration with U.S. biotech company Metaphore Biotechnologies to develop up to two
Novo Nordisk ties up with Metaphore to develop new obesity drugs
Novo Nordisk signed a research tie-up with U.S. biotech firm Metaphore on Thursday to develop next-generation obesity drugs.
Novo Nordisk, Flagship to develop next-generation obesity drugs
Flagship Pioneering’s Metaphore unit announced a new collaboration with partner Novo Nordisk (NVO) for the research and development of next-generation obesity management treatments. The collaboration will utilize Metaphore’s MIMIC platform for the discovery and development of up to two therapeutics targeted at the GLP-1 receptor and related
Local obesity drug developer lands deal worth up to $600M with Novo Nordisk
An obesity-focused startup that spun out of Cambridge’s Flagship Pioneering last year has forged a partnership with the Danish pharmaceutical giant behind weight-loss drugs Ozempic and Wegovy.
Experimental weight-loss procedure could lower appetite by singeing part of stomach
An experimental procedure could reduce levels of a hunger-triggering hormone by burning part of a person's stomach lining, a ...
Weight-loss drugs are a risky but real solution to a lot of health problems: Johann Hari
The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs' author Johann Hari discusses the side effects ...
Experimental Weight Loss Procedure 'Burns’ Stomach Lining to Curb Food Cravings
In a new small trial of an experimental procedure, patients lost about 8% of their baseline weight and experienced a ...
Marketplace1d
New drugs transform weight loss industry
The focus of the event will be the changes in the way we talk about obesity and diet culture, thanks to a new class of drugs ...
The Fight Against Obesity: Weight Loss Medications vs. Bariatric Surgery
The topic of weight loss, especially regarding celebrity extreme weight loss, has recently gained significant attention in ...
Reuters7d
Weight-loss drug Wegovy: How much does it cost and where is it sold?
opens new tab has launched its wildly popular weight-loss drug Wegovy in 10 countries since 2021 at prices ranging from $200 to almost $2,000 a month as Eli Lilly (LLY.N) , opens new tab starts ...